Literature DB >> 18636955

Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries.

Carlos Acuna-Villaorduna1, Anna Vassall, German Henostroza, Carlos Seas, Humberto Guerra, Lucy Vasquez, Nora Morcillo, Juan Saravia, Richard O'Brien, Mark D Perkins, Jane Cunningham, Luis Llanos-Zavalaga, Eduardo Gotuzzo.   

Abstract

BACKGROUND: Resistance to commonly used antituberculosis drugs is emerging worldwide. Conventional drug-susceptibility testing (DST) methods are slow and demanding. Alternative, rapid DST methods would permit the early detection of drug resistance and, in turn, arrest tuberculosis transmission.
METHODS: A cost-effectiveness analysis of 5 DST methods was performed in the context of a clinical trial that compared rapid with conventional DST methods. The methods under investigation were direct phage-replication assay (FASTPlaque-Response; Biotech), direct amplification and reverse hybridization of the rpoB gene (INNO-LiPA; Innogenetics), indirect colorimetric minimum inhibitory concentration assay (MTT; ICN Biomedicals), and direct proportion method on Löwenstein-Jensen medium. These were compared with the widely used indirect proportion method on Löwenstein-Jensen medium.
RESULTS: All alternative DST methods were found to be cost-effective, compared with other health care interventions. DST methods also generate substantial cost savings in settings of high prevalence of multidrug-resistant tuberculosis. Excluding the effects of transmission, the direct proportion method on Löwenstein-Jensen medium was the most cost-effective alternative DST method for patient groups with prevalences of multidrug-resistant tuberculosis of 2%, 5%, 20%, and 50% (cost in US$2004, $94, $36, $8, and $2 per disability-adjusted life year, respectively).
CONCLUSION: Alternative, rapid methods for DST are cost-effective and should be considered for use by national tuberculosis programs in middle-income countries.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18636955     DOI: 10.1086/590010

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

1.  Closing the book on Category II: time for individualized regimens for patients with recurrent tuberculosis.

Authors:  Sara C Auld; Neel R Gandhi; N Sarita Shah
Journal:  Int J Tuberc Lung Dis       Date:  2018-10-01       Impact factor: 2.373

Review 2.  Drug-resistant tuberculosis: an insurmountable epidemic?

Authors:  Amitabha Chakroborty
Journal:  Inflammopharmacology       Date:  2010-12-03       Impact factor: 4.473

Review 3.  Alternative methods of diagnosing drug resistance--what can they do for me?

Authors:  David A J Moore; N Sarita Shah
Journal:  J Infect Dis       Date:  2011-11-15       Impact factor: 5.226

4.  Clinical prediction rule for stratifying risk of pulmonary multidrug-resistant tuberculosis.

Authors:  Dalila Martínez; Gustavo Heudebert; Carlos Seas; German Henostroza; Martin Rodriguez; Carlos Zamudio; Robert M Centor; Cesar Herrera; Eduardo Gotuzzo; Carlos Estrada
Journal:  PLoS One       Date:  2010-08-11       Impact factor: 3.240

Review 5.  Emerging technologies for monitoring drug-resistant tuberculosis at the point-of-care.

Authors:  Vigneshwaran Mani; ShuQi Wang; Fatih Inci; Gennaro De Libero; Amit Singhal; Utkan Demirci
Journal:  Adv Drug Deliv Rev       Date:  2014-06-02       Impact factor: 15.470

6.  Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005-2008.

Authors:  Gustavo E Velásquez; Martin Yagui; J Peter Cegielski; Luis Asencios; Jaime Bayona; Cesar Bonilla; Hector O Jave; Gloria Yale; Carmen Suárez; Sidney Atwood; Carmen C Contreras; Sonya S Shin
Journal:  Emerg Infect Dis       Date:  2011-03       Impact factor: 6.883

7.  Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis.

Authors:  David W Dowdy; Adithya Cattamanchi; Karen R Steingart; Madhukar Pai
Journal:  PLoS Med       Date:  2011-07-26       Impact factor: 11.069

8.  Implementation of HIV and Tuberculosis Diagnostics: The Importance of Context.

Authors:  Joyelle K Dominique; Alberto A Ortiz-Osorno; Joseph Fitzgibbon; Devasena Gnanashanmugam; Christopher Gilpin; Timothy Tucker; Sheila Peel; Trevor Peter; Peter Kim; Steven Smith
Journal:  Clin Infect Dis       Date:  2015-10-15       Impact factor: 9.079

9.  Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation.

Authors:  Nicolas A Menzies; Ted Cohen; Hsien-Ho Lin; Megan Murray; Joshua A Salomon
Journal:  PLoS Med       Date:  2012-11-20       Impact factor: 11.069

10.  Cost-effectiveness of improvements in diagnosis and treatment accessibility for tuberculosis control in India.

Authors:  S-C Suen; E Bendavid; J D Goldhaber-Fiebert
Journal:  Int J Tuberc Lung Dis       Date:  2015-09       Impact factor: 3.427

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.